Prof Jan Wehkamp
University of Tübingen, Germany
Professor Jan Wehkamp studied Medicine at the University of Lübeck and obtained the title of Dr. med. in Internal Medicine in 2002. He started his dissertation and scientific work on chronic inflammatory bowel diseases in 1997 under Prof. Dr. Eduard F. Stange which was followed by four years of postdoctoral training in Germany and the USA (University of Kiel, the Cleveland Clinic and the University of California [UC] Davis School of Medicine). In 2004 he was appointed to a junior faculty position in the Department of Medical Microbiology and Immunology at UC Davis School of Medicine.
He returned to Germany in 2006 to work at the Dr Margarete Fischer-Bosch Institute for Clinical Pharmacology in Stuttgart where he was a DFG/German Research Foundation-Emmy Noether research group leader until 2011. During that time, he was trained and board-certified as clinical pharmacologist (2010). He was awarded a grant of the European Research Council (ERC) for the period 2013-2018 and in 2014 he became Heisenberg Professor of Innate Immunity, Internal Medicine at the University Hospital Tübingen (Germany), speaker of the German Crohn’s Disease/Ulcerative Colitis Association (DCCV, Deutsche Morbus Crohn/Colitis Ulcerosa Vereinigung) and a board member of Defensin Therapeutics. In 2016 he was board-certified in Gastroenterology. Since 2017 he is a senior physician in Internal Medicine responsible for the Inflammatory Bowel Diseases and Gastrointestinal Diseases Study Unit and was nominated as German Top specialist for intestinal diseases (IBD). He also chairs the Alfred Nissle Society and the German Society for Mucosal Immunology.
He has authored more than 100 publications on the molecular mechanisms of chronic inflammatory barrier diseases (e.g. intestine, lung and others), regulation and mechanisms of action of antimicrobial peptides, therapeutic application of antimicrobial peptides and drug development.